{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:46:08Z","timestamp":1792633568370,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While current chemotherapy has increased cure rates for children with acute lymphoblastic leukaemia (ALL), the largest number of relapsing patients are still stratified as medium risk (MR) at diagnosis (50\u201360%). This highlights an opportunity to develop improved relapse-prediction models for MR patients. We hypothesised that bone marrow from MR patients who eventually relapsed would regrow faster in a patient-derived xenograft (PDX) model after induction chemotherapy than samples from patients in long-term remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Diagnostic bone marrow aspirates from 30 paediatric MR-ALL patients (19 who relapsed, 11 who experienced remission) were inoculated into immune-deficient (NSG) mice and subsequently treated with either control or an induction-type regimen of vincristine, dexamethasone, and <jats:italic>L<\/jats:italic>-asparaginase (VXL). Engraftment was monitored by enumeration of the proportion of human CD45<jats:sup>+<\/jats:sup> cells (%huCD45<jats:sup>+<\/jats:sup>) in the murine peripheral blood, and events were defined a priori as the time to reach 1% huCD45<jats:sup>+<\/jats:sup>, 25% huCD45<jats:sup>+<\/jats:sup> (TT25%) or clinical manifestations of leukaemia (TTL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The TT25% value significantly predicted MR patient relapse. Mutational profiles of PDXs matched their tumours of origin, with a clonal shift towards relapse observed in one set of VXL-treated PDXs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, establishing PDXs at diagnosis and subsequently applying chemotherapy has the potential to improve relapse prediction in paediatric MR-ALL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-0933-4","type":"journal-article","created":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T23:02:41Z","timestamp":1592175761000},"page":"742-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia"],"prefix":"10.1038","volume":"123","author":[{"given":"Abdulmohsen M.","family":"Alruwetei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Bendak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babasaheb D.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Carol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Mayoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-9071","authenticated-orcid":false,"given":"Richard B.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"933_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541\u20131552 (2015).","journal-title":"N. Engl. J. Med."},{"key":"933_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","volume":"120","author":"F Locatelli","year":"2012","unstructured":"Locatelli, F., Schrappe, M., Bernardo, M. E. & Rutella, S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120, 2807\u20132816 (2012).","journal-title":"Blood"},{"key":"933_CR3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","volume":"109","author":"KR Schultz","year":"2007","unstructured":"Schultz, K. R., Pullen, D. J., Sather, H. N., Shuster, J. J., Devidas, M., Borowitz, M. J. et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children\u2019s Cancer Group (CCG). Blood 109, 926\u2013935 (2007).","journal-title":"Blood"},{"key":"933_CR4","volume":"5","author":"H Zhang","year":"2015","unstructured":"Zhang, H., Cheng, H., Wang, Q., Zeng, X., Chen, Y., Yan, J. et al. An advanced fragment analysis-based individualized subtype classification of pediatric acute lymphoblastic leukemia. Sci. Rep. 5, 12435 (2015).","journal-title":"Sci. Rep."},{"key":"933_CR5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.15056","volume":"180","author":"R Sutton","year":"2018","unstructured":"Sutton, R., Venn, N. C., Law, T., Boer, J. M., Trahair, T. N., Ng, A. et al. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children. Br. J. Haematol. 180, 550\u2013562 (2018).","journal-title":"Br. J. Haematol."},{"key":"933_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/asheducation.V2014.1.181.3882466","volume":"2014","author":"S Alexander","year":"2014","unstructured":"Alexander, S. Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2014, 181\u2013189 (2014).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"933_CR7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/leu.2013.44","volume":"27","author":"GM Marshall","year":"2013","unstructured":"Marshall, G. M., Dalla Pozza, L., Sutton, R., Ng, A., de Groot-Kruseman, H. A., van der Velden, V. H. et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 27, 1497\u20131503 (2013).","journal-title":"Leukemia"},{"key":"933_CR8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.hoc.2009.07.009","volume":"23","author":"S Jeha","year":"2009","unstructured":"Jeha, S. & Pui, C. H. Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. 23, 973\u2013990 (2009).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"933_CR9","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"Conter, V., Bartram, C. R., Valsecchi, M. G., Schrauder, A., Panzer-Grumayer, R., Moricke, A. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206\u20133214 (2010).","journal-title":"Blood"},{"key":"933_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(07)60073-7","volume":"369","author":"V Conter","year":"2007","unstructured":"Conter, V., Valsecchi, M. G., Silvestri, D., Campbell, M., Dibar, E., Magyarosy, E. et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 369, 123\u2013131 (2007).","journal-title":"Lancet"},{"key":"933_CR11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2015.359","volume":"30","author":"R Marke","year":"2016","unstructured":"Marke, R., Havinga, J., Cloos, J., Demkes, M., Poelmans, G., Yuniati, L. et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 30, 1599\u20131603 (2016).","journal-title":"Leukemia"},{"key":"933_CR12","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","volume":"27","author":"G Basso","year":"2009","unstructured":"Basso, G., Veltroni, M., Valsecchi, M. G., Dworzak, M. N., Ratei, R., Silvestri, D. et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J. Clin. Oncol. 27, 5168\u20135174 (2009).","journal-title":"J. Clin. Oncol."},{"key":"933_CR13","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/leu.2012.101","volume":"26","author":"C Palmi","year":"2012","unstructured":"Palmi, C., Vendramini, E., Silvestri, D., Longinotti, G., Frison, D., Cario, G. et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 26, 2245\u20132253 (2012).","journal-title":"Leukemia"},{"key":"933_CR14","doi-asserted-by":"crossref","first-page":"e76455","DOI":"10.1371\/journal.pone.0076455","volume":"8","author":"M Karsa","year":"2013","unstructured":"Karsa, M., Dalla Pozza, L., Venn, N. C., Law, T., Shi, R., Giles, J. E. et al. Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease. PLoS ONE 8, e76455 (2013).","journal-title":"PLoS ONE"},{"key":"933_CR15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla, M., Dagdan, E., Zaliova, M., Moricke, A., Palmi, C., Cazzaniga, G. et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J. Clin. Oncol. 36, 1240\u20131249 (2018).","journal-title":"J. Clin. Oncol."},{"key":"933_CR16","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.3324\/haematol.2016.162925","volume":"102","author":"SL Heatley","year":"2017","unstructured":"Heatley, S. L., Sadras, T., Kok, C. H., Nievergall, E., Quek, K., Dang, P. et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica 102, e490\u2013e493 (2017).","journal-title":"Haematologica"},{"key":"933_CR17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/MOH.0000000000000349","volume":"24","author":"M Pizzi","year":"2017","unstructured":"Pizzi, M. & Inghirami, G. Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease? Curr. Opin. Hematol. 24, 384\u2013392 (2017).","journal-title":"Curr. Opin. Hematol."},{"key":"933_CR18","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/leu.2016.192","volume":"30","author":"L Jones","year":"2016","unstructured":"Jones, L., Carol, H., Evans, K., Richmond, J., Houghton, P. J., Smith, M. A. et al. A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia 30, 2133\u20132141 (2016).","journal-title":"Leukemia"},{"key":"933_CR19","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V99.11.4100","volume":"99","author":"RB Lock","year":"2002","unstructured":"Lock, R. B., Liem, N., Farnsworth, M. L., Milross, C. G., Xue, C., Tajbakhsh, M. et al. The nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99, 4100\u20134108 (2002).","journal-title":"Blood"},{"key":"933_CR20","volume":"15","author":"NC Wong","year":"2014","unstructured":"Wong, N. C., Bhadri, V. A., Maksimovic, J., Parkinson-Bates, M., Ng, J., Craig, J. M. et al. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics 15, 416 (2014).","journal-title":"BMC Genomics"},{"key":"933_CR21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jim-2016-000076","volume":"64","author":"OL Francis","year":"2016","unstructured":"Francis, O. L., Milford, T. A., Beldiman, C. & Payne, K. J. Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia. J. Investig. Med. 64, 740\u2013744 (2016).","journal-title":"J. Investig. Med."},{"key":"933_CR22","doi-asserted-by":"crossref","first-page":"e9443","DOI":"10.15252\/emmm.201809443","volume":"10","author":"P Richter-Pechanska","year":"2018","unstructured":"Richter-Pechanska, P., Kunz, J. B., Bornhauser, B., von Knebel Doeberitz, C., Rausch, T., Erarslan-Uysal, B. et al. PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. EMBO Mol. Med. 10, e9443 (2018).","journal-title":"EMBO Mol. Med."},{"key":"933_CR23","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2003-08-2911","volume":"103","author":"NL Liem","year":"2004","unstructured":"Liem, N. L., Papa, R. A., Milross, C. G., Schmid, M. A., Tajbakhsh, M., Choi, S. et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103, 3905\u20133914 (2004).","journal-title":"Blood"},{"key":"933_CR24","doi-asserted-by":"crossref","first-page":"44749","DOI":"10.18632\/oncotarget.17432","volume":"8","author":"NJ Davies","year":"2017","unstructured":"Davies, N. J., Kwok, M., Gould, C., Oldreive, C. E., Mao, J., Parry, H. et al. Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget 8, 44749\u201344760 (2017).","journal-title":"Oncotarget"},{"key":"933_CR25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2010-11-320309","volume":"118","author":"M Schmitz","year":"2011","unstructured":"Schmitz, M., Breithaupt, P., Scheidegger, N., Cario, G., Bonapace, L., Meissner, B. et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 118, 1854\u20131864 (2011).","journal-title":"Blood"},{"key":"933_CR26","doi-asserted-by":"crossref","first-page":"e33894","DOI":"10.1371\/journal.pone.0033894","volume":"7","author":"B Szymanska","year":"2012","unstructured":"Szymanska, B., Wilczynska-Kalak, U., Kang, M. H., Liem, N. L. M., Carol, H., Boehm, I. et al. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS ONE 7, e33894 (2012).","journal-title":"PLoS ONE"},{"key":"933_CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ccr.2010.11.014","volume":"19","author":"LH Meyer","year":"2011","unstructured":"Meyer, L. H., Eckhoff, S. M., Queudeville, M., Kraus, J. M., Giordan, M., Stursberg, J. et al. Early relapse in ALL is identified by time to leukemia in NOD\/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell 19, 206\u2013217 (2011).","journal-title":"Cancer Cell"},{"key":"933_CR28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner, S. N., Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"933_CR29","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1608420113","volume":"113","author":"K Oshima","year":"2016","unstructured":"Oshima, K., Khiabanian, H., da Silva-Almeida, A. C., Tzoneva, G., Abate, F., Ambesi-Impiombato, A. et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 113, 11306\u201311311 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"933_CR30","doi-asserted-by":"crossref","first-page":"26711","DOI":"10.18632\/oncotarget.25475","volume":"9","author":"JK Lamba","year":"2018","unstructured":"Lamba, J. K., Cao, X., Raimondi, S. C., Rafiee, R., Downing, J. R., Lei, S. et al. Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. Oncotarget 9, 26711\u201326723 (2018).","journal-title":"Oncotarget"},{"key":"933_CR31","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma, X., Edmonson, M., Yergeau, D., Muzny, D. M., Hampton, O. A., Rusch, M. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat. Commun. 6, 6604 (2015).","journal-title":"Nat. Commun."},{"key":"933_CR32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/leu.2011.212","volume":"26","author":"P Diamanti","year":"2012","unstructured":"Diamanti, P., Cox, C. V. & Blair, A. Comparison of childhood leukemia initiating cell populations in NOD\/SCID and NSG mice. Leukemia 26, 376\u2013380 (2012).","journal-title":"Leukemia"},{"key":"933_CR33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cam4.357","volume":"4","author":"M Ilie","year":"2015","unstructured":"Ilie, M., Nunes, M., Blot, L., Hofman, V., Long-Mira, E., Butori, C. et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med. 4, 201\u2013211 (2015).","journal-title":"Cancer Med."},{"key":"933_CR34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2014.11.024","volume":"357","author":"C Hao","year":"2015","unstructured":"Hao, C., Wang, L., Peng, S., Cao, M., Li, H., Hu, J. et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 357, 179\u2013185 (2015).","journal-title":"Cancer Lett."},{"key":"933_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1242\/dmm.028274","volume":"10","author":"I Holen","year":"2017","unstructured":"Holen, I., Speirs, V., Morrissey, B. & Blyth, K. In vivo models in breast cancer research: progress, challenges and future directions. Dis. Model Mech. 10, 359\u2013371 (2017).","journal-title":"Dis. Model Mech."},{"key":"933_CR36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nm.3915","volume":"21","author":"AA Alizadeh","year":"2015","unstructured":"Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C. et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846\u2013853 (2015).","journal-title":"Nat. Med."},{"key":"933_CR37","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/leu.2017.140","volume":"31","author":"A Elder","year":"2017","unstructured":"Elder, A., Bomken, S., Wilson, I., Blair, H. J., Cockell, S., Ponthan, F. et al. Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia. Leukemia 31, 2577\u20132586 (2017).","journal-title":"Leukemia"},{"key":"933_CR38","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.12442","volume":"162","author":"DT Teachey","year":"2013","unstructured":"Teachey, D. T. & Hunger, S. P. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 162, 606\u2013620 (2013).","journal-title":"Br. J. Haematol."},{"key":"933_CR39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","volume":"101","author":"AV Moorman","year":"2016","unstructured":"Moorman, A. V. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 101, 407\u2013416 (2016).","journal-title":"Haematologica"},{"key":"933_CR40","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3324\/haematol.2018.204974","volume":"104","author":"M Zaliova","year":"2019","unstructured":"Zaliova, M., Stuchly, J., Winkowska, L., Musilova, A., Fiser, K., Slamova, M. et al. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica 104, 1396\u20131406 (2019).","journal-title":"Haematologica"},{"key":"933_CR41","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/sj.leu.2401962","volume":"14","author":"OB Eden","year":"2000","unstructured":"Eden, O. B., Harrison, G., Richards, S., Lilleyman, J. S., Bailey, C. C., Chessells, J. M. et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 14, 2307\u20132320 (2000).","journal-title":"Leukemia"},{"key":"933_CR42","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.leu.2401973","volume":"14","author":"M Schrappe","year":"2000","unstructured":"Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W. D., Henze, G. et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14, 2205\u20132222 (2000).","journal-title":"Leukemia"},{"key":"933_CR43","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ijc.30472","volume":"140","author":"D Wang","year":"2017","unstructured":"Wang, D., Pham, N. A., Tong, J., Sakashita, S., Allo, G., Kim, L. et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int. J. Cancer 140, 662\u2013673 (2017).","journal-title":"Int. J. Cancer"},{"key":"933_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/leu.2016.166","volume":"31","author":"K Wang","year":"2017","unstructured":"Wang, K., Sanchez-Martin, M., Wang, X., Knapp, K. M., Koche, R., Vu, L. et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia 31, 151\u2013158 (2017).","journal-title":"Leukemia"},{"key":"933_CR45","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Koster, J., DeSouza, T. A. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29, 574\u2013586 (2016).","journal-title":"Cancer Cell"},{"key":"933_CR46","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318\u20131325 (2015).","journal-title":"Nat. Med."},{"key":"933_CR47","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David, U., Ha, G., Tseng, Y. Y., Greenwald, N. F., Oh, C., Shih, J. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567\u20131575 (2017).","journal-title":"Nat. Genet."},{"key":"933_CR48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","volume":"30","author":"S Ebinger","year":"2016","unstructured":"Ebinger, S., Ozdemir, E. Z., Ziegenhain, C., Tiedt, S., Castro Alves, C., Grunert, M. et al. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell 30, 849\u2013862 (2016).","journal-title":"Cancer Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0933-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:08:56Z","timestamp":1684616936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0933-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0933-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental studies were approved by the Human Research Ethics Committees of the South Eastern Sydney Area Health Service and the University of New South Wales and performed in accordance with the Declaration of Helsinki. Prior written consent had been obtained for the use of primary ALL samples in research. All animal studies were approved by the Animal Care and Ethics Committee of the University of New South Wales (ACEC licences 12_29A and 15_15B) under guidelines provided in the Australian code for the care and use of animals for scientific purposes (8th Edition 2013).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data associated with this study are available from the authors upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was funded by grants from the Steven Walter Children\u2019s Cancer Foundation, the National Health and Medical Research Council of Australia (NHMRC Fellowships APP1059804 and APP1157871 to R.B.L. and NHMRC Project Grant APP1024232) and Qassim University.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}